A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival

Seminars in Oncology

Volumn 43, Issue 6, 2016, Pages 682-689

  Kazandjian, Dickran ^a   Landgren, Ola ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Approvals; EMA; FDA; Myeloma; Smoldering

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; NEW DRUG; PROTEASOME INHIBITOR; IMMUNOLOGIC FACTOR;

CANCER PATIENT; CANCER SURVIVAL; DRUG APPROVAL; HUMAN; META ANALYSIS (TOPIC); MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; DRUG DEVELOPMENT; MORTALITY;

ANTIBODIES, MONOCLONAL; DRUG APPROVAL; DRUG DISCOVERY; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; PROTEASOME INHIBITORS;

EID: 85007401617     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2016.10.008     Document Type: Review

References (50)

1. [1] Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111 (2008), 2516–2520.
2. [2] Landgren, O., Owen, R.G., Better therapy requires better response evaluation: paving the way for minimal residual disease testing for every myeloma patient. Cytometry Clin Cytometry 90 (2016), 14–20.
3. [3] Landgren, O., Devlin, S., Boulad, M., Mailankody, S., Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis. Bone Marrow Transplant, 2016 Epub ahead of print. http://dx.doi.org/10.1038/bmt.2016.222.
4. [4] Munshi, N.C., Avet-Loiseau, H., Rawstron, A.C., et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A meta-analysis. JAMA Oncol, 2016 Epub ahead of print. http://dx.doi.org/10.1001/jamaoncol.2016.3160.
5. [5] Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328-e346.
6. [6] FDA Thalidomide Drug Label (United States Prescribing Information). Accessed 10/13/2016, at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2eda833b-1357-4ed4-a093-194524fcb061.
7. [7] FDA Lenalidomide Drug Label (United States Prescribing Information). Accessed 10/13/2016, at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be.
8. [8] EMA Thalidomide Drug Label (EPAR Poduct Information). Accessed 10/13/2016, at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000823/WC500037050.pdf.
9. [9] EMA Lenalidomide Drug Label (EPAR Poduct Information). Accessed 10/13/2016, at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000717/WC500056018.pdf.
10. [10] EMA Pomalidomide Drug Label (EPAR Poduct Information). Accessed 10/13/2016, at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002682/WC500147717.pdf.
11. [11] FDA Pomalidomide Drug Label (United States Prescribing Information). Accessed 10/13/2016, at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66.
12. [12] Richardson, P.G., Siegel, D.S., Vij, R., et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 123 (2014), 1826–1832.
13. [13] FDA Bortezomib Drug Label (United States Prescribing Information). Accessed 10/13/2016, at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1521d321-e724-4ffc-adad-34bf4f44fac7.
14. [14] EMA Bortezomib Drug Label (EPAR Poduct Information). Accessed 10/13/2016, at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000539/WC500048471.pdf.
15. [15] FDA Carfilzomib Drug Label (United States Prescribing Information). Accessed 10/13/2016, at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.
16. [16] Stewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372 (2015), 142–152.
17. [17] Richardson, P.G., Sonneveld, P., Schuster, M., Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110 (2007), 3557–3560.
18. [18] EMA Carfilzomib Drug Label (EPAR Poduct Information). Accessed 10/13/2016, at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003790/WC500197692.pdf.
19. [19] Moreau, P., Masszi, T., Grzasko, N., et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374 (2016), 1621–1634.
20. [20] Positive opinion on the marketing authorisation for Ninlaro (ixazomib): outcome of re-examination. 9/16/2016. Accessed 10/13/2016, at http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2016/09/WC500212895.pdf.
21. [21] FDA Panobinostat Drug Label (United States Prescribing Information). Accessed 10/13/2016, at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7774972a-eeaa-4b9a-9e56-3fc1b968e86a.
22. [22] San-Miguel JF, Hungria VTM, Yoon S-S, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014;15:1195-1206.
23. [23] Summary Minutes of the Oncologic Drugs Advisory Committee Meeting. 11/6/2014. Accessed 10/13/2016, at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM430826.pdf.
24. [24] FDA. FDA News Release: FDA approves Farydak for treatment of multiple myeloma. 2/23/2015.
25. [25] Panobinostat drug label. Accessed 10/13/2016, at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7774972a-eeaa-4b9a-9e56-3fc1b968e86a.
26. [26] EMA Panobinstat Drug Label (EPAR Poduct Information). Accessed 10/13/2016, at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003725/WC500193298.pdf.
27. [27] FDA Daratumumab Drug Label (United States Prescribing Information). Accessed 10/13/2016, at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4d0efe9-5e54-467e-9eb4-56fa7d53b60b.
28. [28] EMA Daratumumab Drug Label (EPAR Poduct Information). Accessed 10/13/2016, at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004077/WC500207296.pdf.
29. [29] Palumbo, A., Chanan-Khan, A., Weisel, K., et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375 (2016), 754–766.
30. [30] Dimopoulos, M.A., Oriol, A., Nahi, H., et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375 (2016), 1319–1331.
31. [31] Zonder, J.A., Mohrbacher, A.F., Singhal, S., et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 120 (2012), 552–559.
32. [32] Lonial, S., Dimopoulos, M., Palumbo, A., et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373 (2015), 621–631.
33. [33] FDA Elotuzumab Drug Label (United States Prescribing Information). (Accessed 10/13/2016, at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80686b7e-f6f4-4154-b5c0-c846425e2d91.).
34. [34] EMA Elotuzumab Drug Label (EPAR Poduct Information). Accessed 10/13/2016, at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003967/WC500206673.pdf.
35. [35] Kazandjian, D., Blumenthal, G.M., Luo, L., et al. Benefit-risk summary of crizotinib for the treatment of patients with ROS1 alteration-positive, metastatic non-small cell lung cancer. Oncologist 21 (2016), 974–980.
36. [36] Ali, S.A., Shi, V., Maric, I., et al. T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128 (2016), 1688–1700.
37. [37] Moreau, P., Chanan-Khan, A.A.A., Roberts, A.W., et al. Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. ASCO Meeting Abstracts, 34, 2016, 8011.
38. [38] Kumar, S., Vij, R., Kaufman, J.L., et al. Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma. ASCO Meeting Abstracts, 34, 2016, 8032.
39. [39] Tai, Y.T., Acharya, C., An, G., et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood 127 (2016), 3225–3236.
40. [40] Andrulis, M., Lehners, N., Capper, D., et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Disc 3 (2013), 862–869.
41. [41] Rushworth, S.A., Bowles, K.M., Barrera, L.N., Murray, M.Y., Zaitseva, L., MacEwan, D.J., BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. Cell Signal 25 (2013), 106–112.
42. [42] Sagiv-Barfi, I., Kohrt, H.E.K., Czerwinski, D.K., Ng, P.P., Chang, B.Y., Levy, R., Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A 112 (2015), E966–E972.
43. [43] Vij, R., Huff, C.A., Bensinger, W.I., et al. Ibrutinib, single agent or in combination with dexamethasone, in patients with relapsed or relapsed/refractory multiple myeloma (MM): preliminary phase 2 results. Blood, 124, 2014, 31.
44. [44] Yousef, S., Marvin, J., Steinbach, M., et al. Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. Blood Cancer J, 5, 2015, e285.
45. [45] Sponaas, A.M., Moharrami, N.N., Feyzi, E., et al. PDL1 Expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy. PloS One, 10, 2015, e0139867.
46. [46] Mateos, M.-V., Orlowski, R.Z., Siegel, D.S.D., et al. Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): final efficacy and safety analysis. ASCO Meeting Abstracts, 34, 2016, 8010.
47. [47] Veitonmaki, N., Hansson, M., Zhan, F., et al. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell 23 (2013), 502–515.
48. [48] Shah, J.J., Zonder, J.A., Cohen, A., et al. The novel KSP inhibitor ARRY-520 is active both with and without low-dose dexamethasone in patients with multiple myeloma refractory to bortezomib and lenalidomide: results from a phase 2 study. Blood, 120, 2012, 449.
49. [49] Schmidt, J., Braggio, E., Kortuem, K.M., et al. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia 27 (2013), 2357–2365.
50. [50] Turner, J.G., Dawson, J.L., Grant, S., et al. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Heamtol Oncol, 9, 2016, 73.